Mana.bio’s Post

One of the biotech industry's star investors, the 38-year-old VC firm ARCH Venture Partners, uncorked its 13th fund on Thursday. The Chicago-based firm has another $3 billion to deploy into its large bets on neuroscience, AI, obesity, autoimmune diseases and other areas ripe for more precise treatments. “We’re trying to slow down, but not slowing down because there’s so much cool stuff right now,” managing director Bob Nelsen said Wednesday in an interview with Endpoints News. “Every time we think we’re going to slow down, AI happens or some other thing happens, so it’s an amazing environment to start companies, small ones or big ones, and we do both.” The firm has dished out larger checks and created more startups than most other biotech VC investors over the years. Its current roster includes Xaira Therapeutics, Mirador Therapeutics, Seaport Therapeutics and Metsera among dozens of others. “I’m very hopeful over the next 10 years, and certainly the life of Fund XIII, that we’ll continue to evolve the precision medicine models so that we can better serve patients with lupus, with rheumatoid arthritis, with metabolic disease, cardiovascular disease,” managing director Kristina Burow said in an interview. “Those aren’t just giant, lump diseases. We’re going to start to be able to parse different patients into different medicines.” #biotech #venturecapital #arch #biotechvc #vcfirm #lifesciences

YPOG advised lead investor Vesalius Biocapital IV on the Series C financing round of HepaRegeniX GmbH. Existing investors such as Novo Holdings, Boehringer Ingelheim Venture Fund, and HTGF | High-Tech Gründerfonds also participated in the investment.   The new funding will support the Phases Ib/ IIa clinical trial focused on improving liver healing and preventing liver failure.   Congratulations to our client Vesalius and all parties involved!   The YPOG team was led by Martin Schaper and included Dr. Lutz Schreiber, Benjamin Müller, Matthias Treude as well as Cyra Dittberner.   ➡ Link to the press release in the comments below.   #YPOG #PartnersOfGamechangers #VentureCapital #Growth #Funds #Transactions

Learn more about the rapidly maturing #lifescience sector in Calgary at this panel discussion ⬇

Well done everyone involved! Qureight is a great investment and looking forward to seeing their growth! Echoing Joe - more announcements coming soon from Guinness Ventures so watch this space! 👀 #venturecapital #eis #vct #healthtech #investment #fundraising

As the opportunity to translate breakthrough innovation in biotech into products for patients, remains stronger than ever, it is admirable to see leaders like Ricardo Perdigão Henriques, PhD develop robust, but right-sized investment platforms in underserved markets in Europe. Risk capital is THE critical ingredient to creating a true entrepreneurial culture at the local level. Without sophisticated investors, who know how to pick winners and build companies, it is way too difficult to overcome the huge risks of commercializing biotech products. #innovation #venturecapital #riskreward #entrepreneurship #leadership #culture #emergingmarkets #collaboration #teamwork #strategy

Founders often get crushed by dilution when raising a Series A. Dilution is a product of capital raised and company valuation. Curie.Bio helps founders minimize dilution by maximizing progress with less capital. By reaching critical milestones on blockbuster TPPs, you can raise more capital at a much higher valuation. Last fall, our first portfolio company, Forward Therapeutics, Inc., raised a $50M Series A to generate clinic data. A recent Oppenheimer report revealed this raise was the BIGGEST valuation step up compared to all other therapeutics companies that raised a Series A in the last 12 months. The best part? The founders retained significant ownership in their company. That's the power of the Curie.Bio model. That's how we #freethefounders. If you have an exciting therapeutic idea, we'd love to collaborate. Contact our team or visit our website. https://lnkd.in/e4NWnqwF

If you are planning to make it out to San Francisco next week for the JPM Biotech Showcase 2024, please do send me a note to my email at eric.brewster@pharpoint.com and we would be happy to schedule a time to meet with you and tell you more about PharPoints industry leading timelines (Database ready for sponsor - 15 days after final protocol received) and how we have been able to enroll recent studies well AHEAD of schedule! We look forward to seeing everyone there! #clinicalresearch #clinicaltrials #clinical #pharma #pharmaceutical #biostatistics #biotech #biotechnology #datamanagement

Liquid biopsy testing began as a groundbreaking advancement that revolutionized cancer care and it's now unlocking the power of precision medicine for other life-threatening diseases. Liquid biopsy is a non-invasive diagnostic technique that commonly uses a blood sample to assess biomarkers, offering insights into early disease detection and helping to guide therapeutic decisions through a personalized medicine approach. Liquid biopsy tests are virtually pain-free for patients (versus traditional tissue biopsies) and provide dynamic insights into disease progression by detecting specific genetic changes associated with cancer. Industry leaders like Guardant Health, Foundation Medicine, and more have made groundbreaking contributions to solid tumor testing (cancer occurring in bones, organs, muscles) through innovations in liquid biopsy and FDA-approved companion diagnostics. Liquid biopsy isn’t just limited to cancer, and the applications for its use have expanded significantly as it is now making waves in the world of infectious disease testing. The Karius Test uses next-generation sequencing (NGS) to identify pathogens (i.e., viruses, bacteria, fungi, parasites) directly all from a single blood sample. It’s a game-changer for diagnosing infections in immunocompromised patients, especially in cases where traditional methods may fail. Ultimately, helping to improve the diagnosis and treatment of these potentially life-threatening infections. Congrats to Karius on securing $100M in Series C funding! It is great to see the backing of an innovative company that is making significant advancements in the world of healthcare. #liquidbiopsy #precisionmedicine #moleculardiagnostics #biotechrecruiter

We’re thrilled to announce that we've secured $100 million for our Series C fund, co-led by Khosla Ventures, 5AM Ventures, Gilde Healthcare, and joined by new investor Seventure Partners and existing investor SoftBank Investment Advisers, General Catalyst, HBM Healthcare Investments, Blue Water Life Sciences, Innovation Endeavors, Waycross Partners, and others. These funds enable us to address increasing demand from healthcare providers to expand access to the Karius Test beyond the hospital setting and support research into the broader health implications of Karius’ microbial cell-free DNA technology beyond infectious diseases. Additionally, we're pleased to welcome Alexander A. Morgan, MD PhD from Khosla Ventures, Joep Muijrers from Gilde Healthcare, and Andrew Booth, Venture Advisor at 5AM Ventures and CFO of AbCellera, to our board of directors. Karius' financing coincides with positive results from the PICKUP trial, which enrolled 257 hospitalized adults with pneumonia and hematologic malignancies across 10 leading medical centers. The Karius Test, when added to standard care, detected 40% more infections, potentially changing medical management for 81% of cases, highlighting its diagnostic value in patients with blood cancers or bone marrow transplants and its potential to transform patient care. Thanks to both our new investors as well as existing long-term investors who have participated in the round because of their continued belief in the change Karius can accomplish. https://hubs.li/Q02vTRn20 #funding #healthcare #biotech #KariusTest #AI #AMR #infectiousdisease

Karius’s journey started ten years ago at Stanford, SoftBank has been along for the last four, and today we’re proud to open its next chapter alongside both long-standing and new supporters. The Karius test brings the power of NGS to infectious disease, where it solves not one diagnostic problem but >1,000 at once, mining microbial DNA with ML to identify pathogens and drug-resistance markers. This helps reduce the guesswork of treating infections in the most vulnerable patients, including one half of cancer deaths caused by infection rather than the cancer. This technology has already transformed the care of 10,000s of patients, but we’re just getting started. It’s been a privilege to observe Karius’s remarkable innovation engine that’s set to impact many more diverse clinical settings, and we are confident this financing is the rocket fuel to get there. Here’s to Karius’s next ten years. Vali Barsan, Sumer Juneja